KR102516968B1 - Food composition comprising fermented herbs extract for preventing or improving of immunity, dyspepsia, diarrhea and constipation - Google Patents
Food composition comprising fermented herbs extract for preventing or improving of immunity, dyspepsia, diarrhea and constipation Download PDFInfo
- Publication number
- KR102516968B1 KR102516968B1 KR1020150126000A KR20150126000A KR102516968B1 KR 102516968 B1 KR102516968 B1 KR 102516968B1 KR 1020150126000 A KR1020150126000 A KR 1020150126000A KR 20150126000 A KR20150126000 A KR 20150126000A KR 102516968 B1 KR102516968 B1 KR 102516968B1
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- extract
- lactic acid
- acid bacteria
- mixed
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 48
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 25
- 206010010774 Constipation Diseases 0.000 title claims abstract description 21
- 235000008216 herbs Nutrition 0.000 title claims description 9
- 235000013305 food Nutrition 0.000 title abstract description 64
- 239000000203 mixture Substances 0.000 title abstract description 49
- 201000006549 dyspepsia Diseases 0.000 title abstract description 27
- 230000036039 immunity Effects 0.000 title description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 76
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 239000004310 lactic acid Substances 0.000 claims abstract description 38
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 38
- 238000000638 solvent extraction Methods 0.000 claims abstract 2
- 238000000855 fermentation Methods 0.000 claims description 23
- 230000004151 fermentation Effects 0.000 claims description 23
- 235000010676 Ocimum basilicum Nutrition 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 235000013311 vegetables Nutrition 0.000 claims description 13
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 12
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 12
- 239000001102 lavandula vera Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000018219 lavender Nutrition 0.000 claims description 11
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 10
- 244000062730 Melissa officinalis Species 0.000 claims description 10
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 10
- 244000228451 Stevia rebaudiana Species 0.000 claims description 10
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 235000002020 sage Nutrition 0.000 claims description 9
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 8
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 244000042664 Matricaria chamomilla Species 0.000 claims description 7
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 7
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 241000186612 Lactobacillus sakei Species 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims 2
- 240000007926 Ocimum gratissimum Species 0.000 claims 1
- 240000007673 Origanum vulgare Species 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 239000012676 herbal extract Substances 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 26
- 230000006872 improvement Effects 0.000 abstract description 15
- 230000005965 immune activity Effects 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000000843 powder Substances 0.000 description 26
- 208000002551 irritable bowel syndrome Diseases 0.000 description 19
- 235000005911 diet Nutrition 0.000 description 16
- 230000037213 diet Effects 0.000 description 15
- 235000013361 beverage Nutrition 0.000 description 13
- 244000165082 Lavanda vera Species 0.000 description 12
- 244000180308 Ocimum basilicum Species 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 239000001296 salvia officinalis l. Substances 0.000 description 8
- 240000005183 Lantana involucrata Species 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 235000004357 Mentha x piperita Nutrition 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 244000246386 Mentha pulegium Species 0.000 description 5
- 235000016257 Mentha pulegium Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 235000001050 hortel pimenta Nutrition 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 240000007164 Salvia officinalis Species 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000002912 Salvia officinalis Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229930004069 diterpene Natural products 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000021109 kimchi Nutrition 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RGZSQWQPBWRIAQ-GJZGRUSLSA-N (+)-epi-alpha-bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-GJZGRUSLSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 240000000783 Origanum majorana Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- MONXCRDSDZQGGT-DWIKVQACSA-N [(3r,4ar,6ar,7r,10as,10br)-3-ethenyl-3,4a,7,10a-tetramethyl-2,5,6,6a,8,9,10,10b-octahydro-1h-benzo[f]chromen-7-yl]methanol Chemical compound O1[C@@](C)(C=C)CC[C@@H]2[C@@]3(C)CCC[C@@](C)(CO)[C@@H]3CC[C@]21C MONXCRDSDZQGGT-DWIKVQACSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000000567 diterpene group Chemical group 0.000 description 2
- -1 diterpenoid glycosides Chemical class 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- UUQJTIHOVGMQIH-UHFFFAOYSA-N ladanein Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(O)=C(OC)C=C2O1 UUQJTIHOVGMQIH-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MIZHVKCAJCIZAG-UHFFFAOYSA-N 12alpha-hydroxy-13-epi-manoyloxide Natural products CC1(C)CCCC2(C)C1CCC3(C)OC(C)(C=C)C(O)CC23 MIZHVKCAJCIZAG-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- JLFOFYBNCNKHOL-UHFFFAOYSA-N 3,5,6-Trihydroxy-7,4'-dimethoxyflavone Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(OC)C=C2O1 JLFOFYBNCNKHOL-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- COFSRJDBTTZNBZ-UVTDQMKNSA-N 6-O-Acetylaustroinulin Chemical compound C1CCC(C)(C)C2C(OC(=O)C)C(O)C(C)(O)C(C\C=C(\C)C=C)C21C COFSRJDBTTZNBZ-UVTDQMKNSA-N 0.000 description 1
- COFSRJDBTTZNBZ-UHFFFAOYSA-N 6-O-acetylaustroinulin Natural products CC(=O)OC1C(O)C(C)(O)C(CC=C(C)/C=C)C2(C)CCCC(C)(C)C12 COFSRJDBTTZNBZ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000010701 Lavanda vera Nutrition 0.000 description 1
- 235000002997 Lavandula Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 235000006297 Origanum majorana Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001055080 Peperomia galioides Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- OMHUCGDTACNQEX-OSHKXICASA-N Steviolbioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000488911 Taiwania cryptomerioides Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 208000023505 abnormal feces Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- JLPRGBMUVNVSKP-AHUXISJXSA-M chembl2368336 Chemical compound [Na+].O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C([O-])=O)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O JLPRGBMUVNVSKP-AHUXISJXSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical group O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005302 itopride Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 239000001417 melissa officinalis l. Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229930188195 rebaudioside Natural products 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010993 response surface methodology Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229930186154 sterebin Natural products 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A23Y2220/49—
-
- A23Y2220/67—
-
- A23Y2220/77—
Abstract
본 발명은 발효 허브 추출물을 함유하는 식품 조성물에 관한 것으로 유산균으로 발효된 허브 발효물에 용매 추출하여 얻어지는 발효 허브 추출물의 면역활성, 소화불량, 설사, 변비 예방 및 개선 효과를 실험적으로 확임함으로써 이를 유효성분으로 함유하여 면역활성, 소화불량, 설사, 변비 예방 및 개선기능성을 갖는 식품 조성물을 제공하는 뛰어난 효과가 있다.The present invention relates to a food composition containing a fermented herbal extract, which is effective by experimentally confirming the effects of preventing and improving immune activity, indigestion, diarrhea, and constipation of a fermented herb extract obtained by solvent extraction of a fermented herb fermented with lactic acid bacteria. Contains as a component has an excellent effect of providing a food composition having immune activity, indigestion, diarrhea, constipation prevention and improvement functions.
Description
본 발명은 식물성 유산균 발효 혼합 허브 식물 추출물을 함유하는 면역활성, 소화불량, 설사 및 변비 예방 또는 개선 기능성 식품 조성물에 관한 것이다.The present invention relates to a functional food composition for preventing or improving immune activity, indigestion, diarrhea and constipation, containing a herbal plant extract fermented with vegetable lactic acid bacteria.
유산균(lactic acid bacteria)은 사람이나 동물의 장(腸)과 발효식품 등에서도 쉽게 발견되는 안전한 미생물로(Orrhge, K. et al., 2000, Bifidobacteria and lactobacilli in human health, Drugs Exptl. Clin. Res., 26, 95-111) 장내 상피세포에 부착하여 기생하게 되어 장내 균총의 성질을 개선시켜 장내 균총의 안정화, 유해세균의 정착 억제에 따른 부패산물 생성 감소 및 질병 예방, 면역 활성화 작용, 항암작용, 콜레스테롤 저하 등 인체에 많은 도움을 준다. 유산균이 여러 부패성 미생물 및 병원성 미생물에 대하여 생육억제 작용을 갖는 것은 몇 가지 대사적인 특성 때문인데 유산균은 대사산물로서 항균활성 인자인 organic acid, hydrogen peroxide, reuterin, diacetyl, acetaldehyde, bacteriocin 등을 생산하기 때문이다(Fuller, K., 1989, Probiotics in man and animals, J. Appl. Bacteriol., 66, 365-378). 유산균 배양여액에는 유산균의 발효과정 중 생성된 대사산물로서 감마 아미노뷰티르산(GABA), 아미노산, 펩타이드, 비타민 및 유기산, GABA 등 다양한 생리활성 물질이 함유되어있다(Hur, H.J. et al., In vitro immunopotentiating activities of cellular fractions of lactic acid bacteria isolated from kimchi and bifidobacteria, J. Microbiol. Biotechnol, 16, 661-666, 2006). 최근 건강지향(well-being)을 반영하여 숙주의 건강유지에 유익하게 작용하는 살아있는 미생물 및 이들을 함유한 식품을 뜻하는 프로바이오틱스(probiotics)라는 개념이 도입되어 락토바실러스에 대한 관심이 높아지고 있으며 많은 연구가 진행되고 있다. 이 프로바이오틱스라는 말은 본래 장내 세균총의 밸런스(Balance)를 개선함으로서 숙주동물에 유익하게 작용하는 미생물 첨가물로 정의되어 왔으나 현재는 앞에서 지적한 바와 같이 넓은 의미로 사용하는 경우가 많다(Fuller R., J. Appl. Bacteriol., 66, pp365-378, 1989).Lactic acid bacteria are safe microorganisms that are easily found in human or animal intestines and fermented foods (Orrhge, K. et al., 2000, Bifidobacteria and lactobacilli in human health, Drugs Exptl. Clin. Res ., 26, 95-111) Adheres to epithelial cells in the intestine and becomes parasitic, improving the properties of the intestinal flora, stabilizing the intestinal flora, reducing the production of decay products by inhibiting the settlement of harmful bacteria, preventing diseases, activating immunity, and acting as an anticancer , Cholesterol lowering, etc. It helps the human body a lot. Lactic acid bacteria have a growth inhibitory effect on various putrefactive microorganisms and pathogenic microorganisms because of several metabolic characteristics. Lactic acid bacteria produce antibacterial active factors such as organic acid, hydrogen peroxide, reuterin, diacetyl, acetaldehyde, and bacteriocin as metabolites. (Fuller, K., 1989, Probiotics in man and animals, J. Appl. Bacteriol., 66, 365-378). The lactic acid bacteria culture filtrate is a metabolite produced during the fermentation process of lactic acid bacteria and contains various physiologically active substances such as gamma aminobutyric acid (GABA), amino acids, peptides, vitamins and organic acids, and GABA (Hur, H.J. et al., In vitro immunopotentiating activities of cellular fractions of lactic acid bacteria isolated from kimchi and bifidobacteria, J. Microbiol. Biotechnol, 16, 661-666, 2006). Recently, with the introduction of the concept of probiotics, which refers to living microorganisms and foods containing them, which reflect the well-being and beneficially act on the health of the host, interest in lactobacilli is increasing, and many studies have been conducted. It's going on. The word probiotics has been originally defined as a microbial additive that acts beneficially to host animals by improving the balance of intestinal flora, but now, as pointed out above, it is often used in a broad sense (Fuller R., J. Appl. Bacteriol., 66, pp365-378, 1989).
면역이란 라틴어의 immunitas 라는 어원에서 유래된 말로 외부인자인 항원에 인체가 방어하는 현상을 말한다. 면역에는 태어날 때부터 가지고 있는 선천 면역과 각종 병원체에서 만들어진 백신 등에 의하여 얻어지는 후천성 면역으로 나눌 수 있는데 후천성 면역은 선천 면역을 보강하는 역할을 한다(Ham, S. J. et al., studies on immune stimulation effects of natural amino acid polymer poly-r-glutamic acid, kookmin university, 2012). 면역증강제는 유기 합성이나 추출로 생성한 물질이 주로 이용되지만 독성물질이 잔존할 수 있는 문제점이 있다. 반면에 천연물을 이용하여 추출한 물질을 사용한 경우 천연물이 자연에 존재하는 여러 생물로부터 사람에게 도움이 되는 다양한 물질을 분리하여 얻기 때문에 안정성을 가진다(홍선화, studies on the development of natural immunostimulants originated from herbal extracts, 2010). 유산균의 면역 증강 효과에 대한 메커니즘에 대해서 명확하게 밝혀지지는 않았으나 유산균이 장내에서 서식함으로 장관 면역계에 영향을 미치는 것으로 알려져 있다. Peyer's patch의 림프구들의 항균 활성을 증가시키는 것은 요구르트를 통한 유산균 섭취일 때이고, 실험 동물 및 사람을 대상으로 실행된 일부 연구들에 따르면 유산균은 IgA의 반응을 강화시킨다고 알려져 있다. Immunity is derived from the Latin word immunitas, and refers to the phenomenon in which the body defends itself against antigens, which are external factors. Immunity can be divided into innate immunity, which is present from birth, and acquired immunity obtained by vaccines made from various pathogens. Acquired immunity plays a role in reinforcing innate immunity (Ham, S. J. et al., studies on immune stimulation effects of natural amino acid polymer poly-r-glutamic acid, kookmin university, 2012). Immunity enhancers mainly use substances produced by organic synthesis or extraction, but there is a problem in that toxic substances may remain. On the other hand, when substances extracted from natural products are used, they are stable because natural products are obtained by separating various substances that are useful to humans from various organisms that exist in nature (Seonhwa Hong, studies on the development of natural immunostimulants originated from herbal extracts , 2010). Although the mechanism for the immune enhancing effect of lactic acid bacteria has not been clearly identified, it is known that lactic acid bacteria affect the intestinal immune system by living in the intestine. The antibacterial activity of lymphocytes in Peyer's patch is increased when lactic acid bacteria are consumed through yogurt, and according to some studies performed on experimental animals and humans, lactic acid bacteria are known to enhance the IgA response.
소화불량(functional dyspepsia)은 조직 병리적 및 생화학적인 기질적 병변이 아닌 기능적 증상으로 상복부에 지속적인 불쾌감 또는 통증 등의 증상을 나타내는 질환으로서 의학적으로는 지속 및 반복적으로 상복부에 국한에서 불쾌감이나 통증 등에 따르는 제반증상을 의미한다. 구체적으로 소화불량 중 하나인, 비궤양성 소화불량은 식후 포함감, 식욕부진, 복부 팽만감, 조기 포만감, 트림, 상복부 불쾌감 또는 통증, 속쓰림, 오심(메스꺼움), 구토, 위산 역류, 가슴앓이(heartburn) 등의 소화기계 증상을 모두 포함하며 아직 병태생리가 확실히 밝혀져 있지 않다. 소화불량은 뚜렷한 기질적 병변이 없이 여러 가지 다양한 소화불량 증상에 의한 진단이기 때문에 치료 또한 단순하지 않고, 대부분의 증상이 호전과 악화를 반복하며 음식, 스트레스 등에 의해 변화가 심하다. 대표적 기능성 소화불량 치료제로는 위장관 운동 촉진제로서, 돔페리돈 (Domperidone), 메토클로프라마이드(metoclopramide), 레보설프라이드(levosulpiride), 모사프라이드(mosapride), 이토프라이드(itopride) 등의 약물이 있다(Vincenzo Stanghellini et al., Delayed Gastric Emptying in Functional Dyspepsia, Current Treatment Options in Gastroenterology, 7, 259-264, 2004).Functional dyspepsia is a disease that presents symptoms such as persistent discomfort or pain in the upper abdomen as a functional symptom rather than a histopathological or biochemical organic lesion. means all symptoms. Specifically, nonulcer dyspepsia, one of dyspepsia, is a feeling of inclusion after eating, anorexia, abdominal distension, early satiety, belching, epigastric discomfort or pain, heartburn, nausea (nausea), vomiting, acid reflux, heartburn ), including all digestive system symptoms, and the pathophysiology has not yet been clearly identified. Since dyspepsia is diagnosed by various symptoms of indigestion without clear organic lesions, treatment is not simple, and most symptoms repeat improvement and deterioration, and changes are severe due to food and stress. Representative functional dyspepsia treatments include gastrointestinal motility promoters, such as domperidone, metoclopramide, levosulpiride, mosapride, and itopride ( Vincenzo Stanghellini et al., Delayed Gastric Emptying in Functional Dyspepsia, Current Treatment Options in Gastroenterology, 7, 259-264, 2004).
과민성 대장 증후군(irritable bowel syndrome: IBS)은 삶의 질에 관한 현저한 효과를 갖는 공통적인 대장 기능성 장애이다. 과민성 대장 증후군을 정의하는 특징은 복부 불편(abdominal discomfort) 또는 통증(pain)이다. 과민성 대장 증후군에 관한 Rome Ⅱ 진단 기준(증상에 기초한 기능성 위장관 장애를 진단하기 위한 체계)은 하기와 같다: 하기 특징 중 2 이상을 동반하는 복부 불편 또는 통증이 이전 12개월 중에, 연속적일 필요없는, 12주 이상: (1) 그것이 배변으로 경감되거나, 및/또는 (2) 개시가 배변 빈도의 변화에 연관되어 있고, 및/또는 (3) 개시가 대변 형태(외관)의 변화와 연관되어 있음. 과민성 대장 증후군의 진단을 지지하는 다른 증상은 통증: 비정상적인 대변 통과 (힘주기(straining), 절박성(urgency), 또는 불완전한 배출감); 점액의 통과; 및 더부룩함(bloating) 또는 복부 팽창감을 포함한다. 환자는 그의 잠재적인 배변 습관(bowel habit)에 의해 세분화될 수 있다: (i) 설사 우세형 과민성 대장 증후군, (ii)변비-우세형 과민성 대장 증후군, 및 (iii) 설사와 교대로 발생하는 변비(교대성 과민성 대장 증후군). 과민성 대장 증후군의 병태생리학은 영국 인구의 약 1/4이 상기 증상을 보일 수 있고, 미국 성인의 약 15 %가 과민성 대장 증후군의 진단에 일치하는 증상을 가진 것으로 보고되고 있다는 사실에도 불구하고 잘 이해되고 있지 않다. 과민성 대장 증후군을 갖는 사람의 25%만이 의료적 지원을 구하고 있는 것으로 추정된다. 또한, 과민성 대장 증후군으로 진단된 환자는 섬유근육통(fibromyalgia) 및 간질성 방광염(interstitial cystitis)과 같은 다른, 비-위장관 기능성 장애의 증가된 위험 속에 놓이게 된다. 과민성 대장 증후군은 미국의 위장병학자에 의해 이루어지는 가장 흔한 진단이고, 일차 의료 제공자에 대한 방문자의 12%에게 설명되고 있다. 직접적인 의료 비용으로 약 80억 달러 및 간접적인 비용으로 250억 달러가 매년 미국에서 과민성 대장 증후군을 진단하고 치료하는데 소비된다. 따라서, 과민성 대장 증후군은 미국에서 매년 건강관리 비용의 큰 비율을 차지한다. 과민성 대장 증후군의 일차 치료는 상담 및 식습관 교정을 포함한다. 약물 치료는 개별적인 증상에 지향되는 유익한 것으로 간주된다. 설사 우세형의 경우, 설사는 치료하지만, 복부 통증은 치료하지 않는, 로페라미드와 같은 항설사 약물이 사용될 수 있다. 복부 통증은 과민성 대장 증후군을 정의하는 특징 중 하나이기 때문에, 항설사성 약물은 과민성 대장 증후군을 적절하게 치료하는 것이 아니다(Jailwala 등, 2000, Ann Intern Med. 2000;133:136-147; Cremonini 등, 2004, Minerva Med 95:427-441) 변비 우세형의 경우, 이스파굴라(ispaghula)가 식이 섬유를 증가시키기 위해 종종 사용된다. 환자가 우세한 증상으로서 통증 및 팽창을 갖는 경우에는, 항진경제(antispasmolytics)가 공통적으로 사용된다. 메베베린(mebeverine) 및 페페르민트 오일이 상기 경우에 종종 사용된다. 과민성 대장 증후군을 치료하기 위해 시도되었던 다른 제제들은 다양한 결과를 갖는 베타-차단제, 날록손(naloxone), 온단세트론(ondansetron), 칼슘 채널 차단제, 시메티콘(simethicone), 레우프로레린(leuprorelin), 옥트레오티드(octreotide) 및 콜레시스토키닌(cholecystokinin) 길항제를 포함한다(Martindale, The Extra Pharmacopoeia, 31st Edition(1996)p.1197).Irritable bowel syndrome (IBS) is a common bowel functional disorder with significant effects on quality of life. The defining feature of irritable bowel syndrome is abdominal discomfort or pain. The Rome II diagnostic criteria for irritable bowel syndrome (a system for diagnosing functional gastrointestinal disorder based on symptoms) are as follows: Abdominal discomfort or pain accompanied by two or more of the following characteristics, not necessarily continuous, during the previous 12 months; 12 weeks or longer: (1) it is relieved with bowel movements, and/or (2) the onset is associated with a change in bowel frequency, and/or (3) the onset is associated with a change in stool form (appearance). Other symptoms supporting the diagnosis of irritable bowel syndrome are pain: abnormal stool passage (feeling of straining, urgency, or incomplete emptying); passage of mucus; and bloating or a feeling of distension in the abdomen. Patients can be subdivided by their potential bowel habit: (i) diarrhea-predominant irritable bowel syndrome, (ii) constipation-predominant irritable bowel syndrome, and (iii) constipation alternating with diarrhea. (Alternative Irritable Bowel Syndrome). The pathophysiology of irritable bowel syndrome is well understood, despite the fact that about a quarter of the UK population may have these symptoms, and about 15% of adults in the US report having symptoms consistent with a diagnosis of irritable bowel syndrome. It's not happening. It is estimated that only 25% of people with irritable bowel syndrome seek medical assistance. In addition, patients diagnosed with irritable bowel syndrome are at increased risk of other, non-gastrointestinal functional disorders such as fibromyalgia and interstitial cystitis. Irritable bowel syndrome is the most common diagnosis made by gastroenterologists in the United States, accounting for 12% of visitors to primary care providers. About $8 billion in direct medical costs and $25 billion in indirect costs are spent annually diagnosing and treating irritable bowel syndrome in the United States. Thus, irritable bowel syndrome accounts for a large percentage of annual health care costs in the United States. Primary treatment for irritable bowel syndrome includes counseling and dietary modification. Medication is considered beneficial directed at the individual symptoms. For the diarrhea-predominant type, anti-diarrhea drugs such as loperamide, which treat diarrhea but not abdominal pain, can be used. Because abdominal pain is one of the defining features of irritable bowel syndrome, antidiarrheal drugs do not adequately treat irritable bowel syndrome (Jailwala et al., 2000, Ann Intern Med. 2000;133:136-147; Cremonini et al., 2004, Minerva Med 95:427-441) For the predominant type of constipation, ispaghula is often used to increase dietary fiber. Antispasmolytics are commonly used when the patient has pain and swelling as the predominant symptoms. Mebeverine and peppermint oil are often used in this case. Other agents that have been tried to treat irritable bowel syndrome have been beta-blockers with varying results, naloxone, ondansetron, calcium channel blockers, simethicone, leuprorelin, octreotide. (octreotide) and cholecystokinin antagonists (Martindale, The Extra Pharmacopoeia, 31st Edition (1996) p. 1197).
한편, 허브는 초록색 풀을 의미하는 라틴어인 herba에서 유래되어 꽃과 종자, 줄기, 잎, 뿌리 등이 인간에게 유용하게 사용되는 초본식물로, 예로부터 진통·진정 등의 치료나 방부 및 살충을 위한 약초로서 중요한 역할을 해왔다. 허브에는 인체에 대한 화학물질의 독성, 환경오염에 대한 우려 및 그 뛰어난 효능으로 인하여 많은 주목을 받고 있으며 그 종류로는 로즈마리, 라벤더, 세이지, 바질, 페퍼민트, 캐모마일, 오레가노, 레몬밤, 스테비아 등이 있다.On the other hand, herb is a herbaceous plant derived from the Latin word herba meaning green grass, and its flowers, seeds, stems, leaves, and roots are useful for humans. It has played an important role as a medicinal herb. Herbs are attracting a lot of attention due to the toxicity of chemicals to the human body, concerns about environmental pollution, and their outstanding efficacy. there is.
로즈마리(Rosemarinus officinalis L.)는 지중해 연안이 원산인 상록관목으로 소나무 잎처럼 뾰족한 잎에 장뇌와 비슷한 산뜻하고 강한 향을 지닌 허브로서 주로 향수, 약으로 사용되어 왔으며, 역한 냄새를 제거하는 소취제의 역할, 상큼한 향을 내는 부향제의 역할, 살균작용과 항균작용 및 항산화 효과 등과 식품의 보존성을 높이는 것으로 알려져 있다(Elena I. et al., Supercritical fluid extraction and fractionation of different preprocessed rosemary plants. J Agric Food Chem, 47, P1400-1404, 1999). 강력한 항산화 효과, 골다공증 예방효과, 항암효과, antiAIDS 효과뿐만 아니라 그람 양성균에 대한 항균 활성을 가지며 혈중 알콜농도를 감소시키는 효과 등의 여러 기능성이 보고되었다(Kim J.S. et al., Effect on the Quality characteristics of Korean traditional wines with the addition of rosemary (Rosmarinus officinalis L.), Korean J. Food Cookery Sci., 22, P914-922, 2006).Rosemary (Rosemarinus officinalis L.) is an evergreen shrub native to the Mediterranean coast. It has pointed leaves like pine leaves and has a refreshing and strong scent similar to camphor. It is known to enhance the preservation of food, such as the role of a preservative that gives a fresh fragrance, bactericidal, antibacterial, and antioxidant effects (Elena I. et al., Supercritical fluid extraction and fractionation of different preprocessed rosemary plants. J Agric Food Chem, 47, P1400-1404, 1999). Various functionalities such as strong antioxidant effect, osteoporosis preventive effect, anticancer effect, antiAIDS effect, as well as antibacterial activity against Gram-positive bacteria and an effect of reducing blood alcohol concentration have been reported (Kim J.S. et al., Effect on the Quality characteristics of Korean traditional wines with the addition of rosemary (Rosmarinus officinalis L.), Korean J. Food Cookery Sci., 22, P914-922, 2006).
라벤더(Lavandula angustifolia)는 원산지가 지중해인 쌍떡잎식물 꿀풀과의 한 종류로 라벤더 물 추출물은 mushroom tyrosinase에 대한 저해 활성을 가지고, 에탄올 추출물은 피지 생성을 억제하는 효과가 있다고 보고되어 있다. 라벤더의 주요 성분으로는 linalool, linalyl acetate, ladanein, apigenin, apigenin-7-O-β-glucoside, luteolin, luteolin-7-O-β-glucoside, 5,4'-dihydroxy flavonoid-7-O-β-pyranglycuronate buthyl ester가 함유되어 있다고 알려져 있다(Park S. J. et al., Inhibitory effects of the ethanol extract of Lavandula vera on sebum synthesis, J. Traditional Korean Medicine, 15, P77, 2006). 이 중 rosmarinic acid, hydroxycinnamic acid, 1,8-cineole 등은 L. angustifolia의 항산화 효과에 기여한다고 보고되어 있다(CHU C. J. et al., Lavender(Lavandula spp.), Longwood Herbal Task Force, 1, 2001).Lavender (Lavandula angustifolia) is a dicotyledonous plant of the Lamiaceae family that is native to the Mediterranean. It has been reported that lavender water extract has an inhibitory activity against mushroom tyrosinase, and ethanol extract has an inhibitory effect on sebum production. The major components of lavender include linalool, linalyl acetate, ladanein, apigenin, apigenin-7-O-β-glucoside, luteolin, luteolin-7-O-β-glucoside, and 5,4'-dihydroxy flavonoid-7-O-β. -Pyranglyglycuronate buthyl ester is known to be contained (Park S. J. et al., Inhibitory effects of the ethanol extract of Lavandula vera on sebum synthesis, J. Traditional Korean Medicine, 15, P77, 2006). Among them, rosmarinic acid, hydroxycinnamic acid, and 1,8-cineole have been reported to contribute to the antioxidant effect of L. angustifolia (CHU C. J. et al., Lavender (Lavandula spp.), Longwood Herbal Task Force, 1, 2001). .
세이지(sage, Salvia officinalis L.)는 샐비어, common sage, garden sage라고도 불리며 항박테리아, 진균억제, 바이러스 억제, 수렴제, 분비물 용해제, 발한 억제 효과를 가지고 있다고 하며 동물실험에 항고혈압과 이담작용이 관찰되었다. 약용으로는 잎을 삶아서 인후염 및 위장염에 사용하며 방부, 항균, 항염 등 살균 소독작용이 있고 염증의 소염제로도 이용한다. 또한 중풍이나 심한 운동 뒤의 피로도를 감소시켜준다(Han M. J. et al., One Hundred of Herbs Used for Healing. 1st ed. Hyoil Press, Seoul. Korea, P52-53, 2004).Sage (Salvia officinalis L.) is also called salvia, common sage, and garden sage, and is said to have antibacterial, fungal, viral, astringent, secretion dissolving, and antiperspirant effects. Antihypertensive and choleretic effects were observed in animal experiments. It became. For medicinal use, the leaves are boiled and used for sore throat and gastroenteritis. It also reduces fatigue after stroke or severe exercise (Han M. J. et al., One Hundred of Herbs Used for Healing. 1st ed. Hyoil Press, Seoul. Korea, P52-53, 2004).
바질(Ocimum basilicum L.)은 아프리카, 열대 아시아 지역이 원산지로 현재는 유럽을 비롯한 전세계에서 재배되는 1년생 초본으로 0.5m 크기로 자라는 식물로 건위, 진정, 진경, 구풍 등의 약리작용과 불면증, 구내염 등에도 효과가 있는 것으로 알려져 있으며(Ahn D. J. et al., Comparison of volatile components in organs of organs of Ocimum basilicum L. cultivated in Korea, Korean J. Medicinal Crop. Sci. 9, 130-138, 2001), 바질의 추출물은 저혈당 효과를 가지므로 식이성 치료제 개발 가능성이 있으며, 콜레스테롤 함량을 줄일 수 있다고 보고된 바 있다(Choi E. Y. et al., Optimization of homemade pasta with addition of basil using response surface methodology, Korean J. food Culture, 20, 61-67, 2005).Basil (Ocimum basilicum L.) is an annual herb that is native to Africa and tropical Asia and is now cultivated around the world including Europe. It is a plant that grows to a size of 0.5m. It is known to be effective for stomatitis (Ahn D. J. et al., Comparison of volatile components in organs of organs of Ocimum basilicum L. cultivated in Korea, Korean J. Medicinal Crop. Sci. 9, 130-138, 2001), Since basil extract has a hypoglycemic effect, it has been reported that there is a possibility of developing a dietary treatment and that it can reduce cholesterol content (Choi E. Y. et al., Optimization of homemade pasta with addition of basil using response surface methodology, Korean J. Food Culture, 20, 61-67, 2005).
페퍼민트(Mentha piperita L.)는 국화과에 속하며 향기가 강한 다년생 허브로 전 세계적으로 널리 재배되고 있으며 식품 및 화장품 첨가제, 약품의 원료로 사용되고 있으며(McKay, Diane L. et al., A Review of the Bioactivity and Potential Health Benefits of Peppermint Tea (MenthapiperitaL), Phytother Res., 20, 619-633, 2006) 항산화, 항염, 항알러지, 항바이러스, 항균 등의 효과가 보고 되었다(Mimica-Dukic, N. et al., Antimicrobial and antioxidant activities of three Mentha species essential oils, Planta Med., 69, 413-419, 2003).Peppermint (Mentha piperita L.) belongs to the Asteraceae family and is a perennial herb with strong fragrance. It is widely cultivated worldwide and is used as a raw material for food and cosmetic additives and medicines (McKay, Diane L. et al., A Review of the Bioactivity and Potential Health Benefits of Peppermint Tea (MenthapiperitaL), Phytother Res., 20, 619-633, 2006) Antioxidant, anti-inflammatory, anti-allergic, antiviral, and antibacterial effects have been reported (Mimica-Dukic, N. et al. , Antimicrobial and antioxidant activities of three Mentha species essential oils, Planta Med., 69, 413-419, 2003).
캐모마일(Matricaria chamomilla L.)은 유럽과 인도, 북아프리카가에 널리 자생하며 국화과에 속하며 염증성 질환, 발열, 설사, 소장과 간의 종양을 치료하기 위한 약용 차로 많이 이용되어 왔다(Mann C. et al., Spices and Medical Plants. Recent advances in botany, horticulture and pharmacology, Food Products Press, USA, 1, 235-280, 1986). 꽃에는 terpenes, flavonoides, coumarin, malicacid 및 무기질 성분 등 120여종의 화합물들이 함유되어 있는 것으로 보고되었으며 특히 α-bisabolol은 통풍을 감소하고 의궤양의 진행을 억제시킬 뿐 아니라 피부염 치료에 효과가 있는 것으로 알려져 있다(Cillegas L. F. et al., (+)-epi-α-bisabolol is the wound healing principle of peperomia galioides: investigation of the in vivo wound-healing activity of related terpenoids, J. Nat. Prod., 46, 1357-1358, 2001).Chamomile (Matricaria chamomilla L.) is widely native to Europe, India, and North Africa, belongs to the Asteraceae family, and has been widely used as a medicinal tea to treat inflammatory diseases, fever, diarrhea, and tumors of the small intestine and liver (Mann C. et al., Spices and Medical Plants. Recent advances in botany, horticulture and pharmacology, Food Products Press, USA, 1, 235-280, 1986). It has been reported that flowers contain 120 kinds of compounds, such as terpenes, flavonoides, coumarin, malicacid, and inorganic components. In particular, α-bisabolol is known to be effective in reducing gout, suppressing the progress of ulcers, and treating dermatitis. (Cillegas L. F. et al., (+)-epi-α-bisabolol is the wound healing principle of peperomia galioides: investigation of the in vivo wound-healing activity of related terpenoids, J. Nat. Prod., 46, 1357- 1358, 2001).
오레가노(Origanum majorana L.)는 소엽과의 다년초로서 원산지는 유럽이다. 이탈리아, 멕시코요리에 잘 이용되며 와일드(야생) 마조람이라는 별명대로 야생적인 향기가 있다. 라틴계의 요리나 토마토와 잘 어울린다. 소화촉진, 강장효과가 있으며 차나 입욕제, 건조한 꽃으로 이용한다.Oregano (Origanum majorana L.) is a perennial plant of the lobulaceae family and is native to Europe. It is well used in Italian and Mexican cuisine, and has a wild scent as the nickname Wild (Wild) Marjoram. It goes well with Latin dishes and tomatoes. It promotes digestion and has a tonic effect, and is used as tea, bath additives, and dried flowers.
레몬밤(lemon balm, Melissa officinalis L.)은 주로 잎을 식용으로 사용하며 우울증, 신경성 두통, 기억력 저하, 신경통, 발열 등에 효능이 있으며 뇌의 활동을 높여 기억력을 증진시키며 우울증과 노화를 예방하는데도 좋다고 알려져 있다. 레몬밤은 레몬과 유사한 향이 있는데 이 향은 감정을 편안하게 진정시켜주며 심장 박동수를 낮추어 혈압을 강하시키는 작용을 한다(Korea Food and Drug Administration. Food sources, Apr, 5, 2006)Lemon balm (Melissa officinalis L.) leaves are mainly used for food, and are effective for depression, nervous headache, memory loss, neuralgia, and fever. It is known. Lemon balm has a scent similar to lemon, and this scent calms emotions comfortably and lowers blood pressure by lowering heart rate (Korea Food and Drug Administration. Food sources, Apr, 5, 2006)
스테비아(Stevia rebaudiana Bertoni)는 스테비아속의 숙근성 다년생 초본으로 쌍떡잎식물강 초롱꽃목 국화과이다. 줄기의 길이는 70∼80 cm 정도이고 잎은 길이가 4∼10 cm, 너비가 2.5 cm이고 1899년에 처음 연구되어 100개 이상의 terpenes과 flavonoids 등이 phytochemicals로 함유되어 있는 것으로 알려져 있다(Komisseranko NF. et al, Diterpene glycoside and phenylpropanoid of Stevia rebaudiana bertoni (astercae), 1, 53-64, 1994). 스테비아의 주요성분으로는 diterpenoid glycosides의 steviolbioside, rebaudioside A~E, stevioside 등의 성분이 함유되어 있는 것으로 알려져 있으며, 그 밖에 jhanol, sterebin A-N, 6-O-acetyl-austroinulin 등의 diterpenes 성분이 알려져 있다. 그 중에서 stevioside는 생쥐에 대한 당뇨조절 효과 등이 보고되고 있으며(Lailerd N. et al., Effects of stevioside on glucose transport activity in insulin-sensitive and insulin-resistant rat skeletal muscle, Metabolism, 53, 101-107, 2004), diterpene 화합물들은 항산화, 항박테리아, 항바이러스 등에 효과가 확인되고 있다(Wang B.S. et al., Antioxidant activity of abietane-type diterpenes from heartwood of Taiwania cryptomerioides Hayata, Holzforschung, 56, 487-492, 2002).Stevia (Stevia rebaudiana Bertoni) is a perennial herb belonging to the genus Stevia and belongs to the dicotyledonous class Camphoraceae. The length of the stem is about 70 to 80 cm, and the leaves are 4 to 10 cm long and 2.5 cm wide. It was first studied in 1899 and is known to contain more than 100 terpenes and flavonoids as phytochemicals (Komisseranko NF. et al, Diterpene glycoside and phenylpropanoid of Stevia rebaudiana bertoni (astercae), 1, 53-64, 1994). The main components of stevia are known to contain diterpenoid glycosides such as steviolbioside, rebaudioside A-E, and stevioside, and other diterpenes such as jhanol, sterebin A-N, and 6-O-acetyl-austroinulin. Among them, stevioside has been reported to have a diabetic control effect on mice (Lailerd N. et al., Effects of stevioside on glucose transport activity in insulin-sensitive and insulin-resistant rat skeletal muscle, Metabolism, 53, 101-107, 2004), diterpene compounds have been confirmed to have antioxidant, antibacterial, and antiviral effects (Wang B.S. et al., Antioxidant activity of abietane-type diterpenes from heartwood of Taiwania cryptomerioides Hayata, Holzforschung, 56, 487-492, 2002) .
본 발명의 선행기술로는 신규한 락토바실러스 플란타룸, 이의 제조방법 및 이를 이용한 대장균성 설사병 예방 또는 치료용 조성물이 국내 등록특허 제10-1378673호에 공지되어 있으나 이는 락토바실러스 플란타룸 LP GS 변이균주를 유효성분으로 함유하여 대장균성 설사병 예방 또는 치료용 약학 조성물에 관한 것이다. 또 함초, 민들레, 생강나무 등 125가지의 원재료를 생물의 물성에 따라 CO2(또는 N2) Carrier Gas를 이용하여 추출농축, 설탕 절임 후 추출 및 Microwave와 Filter를 이용하여 추출한 추출물들을 혼합숙성하여 제조한 조성물과 그 제조방법이 국내 등록특허 제 10-1501326호에 공지되어있다. 그러나 상기문헌 어디에도 상기 허브에 유산균을 사용하여 발효시킨 유산균 발효 혼합 허브 추출물을 함유하는 면역활성, 소화불량, 설사 및 변비 예방 또는 개선 기능성 식품 조성물에 대하여는 공지된 바 없다.As the prior art of the present invention, a novel Lactobacillus plantarum, a method for producing the same, and a composition for preventing or treating E. coli diarrhea using the same are known in Korean Patent Registration No. 10-1378673, which is Lactobacillus plantarum LP GS It relates to a pharmaceutical composition for preventing or treating E. coli diarrhea containing a mutant strain as an active ingredient. In addition, 125 raw materials such as seaweed, dandelion, and ginger are extracted and concentrated using CO 2 (or N2) Carrier Gas according to the physical properties of organisms, sugar-pickled, extracted, and mixed and aged with extracts extracted using microwave and filter. A composition and a manufacturing method thereof are known from Korean Registered Patent No. 10-1501326. However, nowhere in the above document is there known about a functional food composition for preventing or improving immune activity, indigestion, diarrhea and constipation containing a lactic acid bacteria fermented mixed herb extract fermented using lactic acid bacteria in the herb.
따라서 본 발명의 목적은 식물성 유산균 발효 혼합 허브 식물 추출물을 함유하는 면역활성, 소화불량, 설사 및 변비 예방 또는 개선 기능성 식품 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a functional food composition for preventing or improving immune activity, indigestion, diarrhea and constipation containing a vegetable lactic acid bacteria fermented mixed herbal plant extract.
본 발명의 상기 목적은 허브를 건조분말화한 다음 고온살균처리하여 발효원료를 준비하는 단계와; 상기 단계에서 얻은 발효원료에 유산균을 접종하고 온도 35~37℃, pH7, 교반속도 100~120rpm의 발효조건에서 3~5일간 발효시켜 발효물을 얻는 단계와; 상기 단계에서 얻은 발효물을 원심분리하여 발효액을 얻는 단계와; 상기 단계에서 얻은 발효액을 추출용매로 열수추출하여 발효추출물을 얻는 단계와; 상기 단계에서 얻은 발효추출물을 여과지로 여과시켜 본 발명 발효허브추출물을 제조하는 단계로 이루어지고, 상기 본 발명 발효허브추출물의 면역활성, 소화불량, 설사 및 변비 예방 또는 개선 효과를 확인하고 식품 조성물 제형을 제조하는 단계를 통하여 달성하였다.The above object of the present invention comprises the steps of preparing a fermented raw material by drying and powdering herbs and then sterilizing them at high temperature; Obtaining a fermented product by inoculating the fermentation raw material obtained in the above step with lactic acid bacteria and fermenting it for 3 to 5 days under fermentation conditions of a temperature of 35 to 37 ° C, pH 7, and a stirring speed of 100 to 120 rpm; Obtaining a fermentation broth by centrifuging the fermentation product obtained in the above step; Obtaining a fermentation extract by hot water extraction of the fermentation broth obtained in the above step with an extraction solvent; Filtering the fermented extract obtained in the above step with a filter paper to prepare the fermented herb extract of the present invention, and confirming the effect of preventing or improving the immune activity, indigestion, diarrhea and constipation of the fermented herb extract of the present invention, and formulating a food composition It was achieved through the steps of preparing.
본 발명은 식물성 유산균으로 발효시킨 혼합 허브 추출물의 면역활성, 소화불량, 설사, 변비에 대한 예방 및 개선 기능성을 확인함으로써 이를 성분으로 함유하는 면역활성, 소화불량, 설사, 변비에 대한 예방 및 개선 기능성 식품 조성물을 제공하는 뛰어난 효과가 있다.The present invention confirms the immune activity, indigestion, diarrhea, and constipation prevention and improvement functionalities of a mixed herb extract fermented with vegetable lactic acid bacteria, thereby preventing and improving immune activity, indigestion, diarrhea, and constipation containing the same as a component. There is an excellent effect of providing a food composition.
도 1은 본 발명 유산균 발효 혼합 허브 추출물 제조방법을 도식화한 그림이다.1 is a diagram illustrating a method for manufacturing a mixed herbal extract fermented with lactic acid bacteria of the present invention.
본 발명 식물성 유산균 발효 혼합 허브 추출물의 제조방법은 다음과 같은 단계로 구성되는 것을 특징으로 한다(도1). 본 발명의 목적을 달성하기에 적합한 허브는 로즈마리, 라벤더, 세이지, 바실, 민트, 캐모마일, 오레가노, 레몬밤 및 스테비아로 이루어지는 그룹에서 선택되는 어느 하나 이상의 조합일 수 있거나 또는 상기 허브들을 동량비의 중량으로 혼합한 것이다.The method for producing a mixed herb extract fermented with vegetable lactic acid bacteria of the present invention is characterized in that it consists of the following steps (Fig. 1). Herbs suitable for achieving the object of the present invention may be any one or more combinations selected from the group consisting of rosemary, lavender, sage, basil, mint, chamomile, oregano, lemon balm and stevia, or the above herbs in equal proportions by weight is mixed with
제1단계:원료 준비Step 1: Raw material preparation
허브를 건조분말화 한 허브분말과 동량의 증류수를 발효조에 넣고 100℃에서 5분간 살균처리한 후 37℃까지 온도를 낮추어 발효원료를 준비한다.
The dry powdered herb powder and the same amount of distilled water are put in a fermenter, sterilized at 100 ° C for 5 minutes, and then the temperature is lowered to 37 ° C to prepare fermented raw materials.
제2단계: 식물성 유산균 발효Step 2: Fermentation of vegetable lactic acid bacteria
유산균 배양배지에서 액상배양한 식물성 유산균을 상기 제1단계의 발효원료에 접종하고 온도 35~37℃, pH 7, 교반속도 100~120rpm의 발효조건에서 3~5일간 발효시킨다.
Vegetable lactic acid bacteria cultured in liquid phase in a lactic acid bacteria culture medium are inoculated into the fermentation raw material of the first step and fermented for 3 to 5 days under fermentation conditions of a temperature of 35 to 37 ° C, a pH of 7, and a stirring speed of 100 to 120 rpm.
제3단계: 유산균 발효 혼합 허브 추출물 제조Step 3: Preparation of lactic acid bacteria fermented mixed herbal extract
제2단계에서 얻은 유산균 발효물을 원심분리하여 침전물과 균체를 제거하고 발효액을 회수한다. 상기 얻은 발효액에 추출용매로 동량의 증류수를 첨가하고 이를 냉각콘덴서가 달린 추출기에서 온도 80℃로 6시간 가열하여 증류되어 나오는 증류액을 회수하고 이와 별도로 상기 단계에서 남은 발효액을 추출용매로 추출하여 발효추출물을 얻는다. 상기에서 얻은 발효추출물은 300메쉬 여과지로 1차 여과하고 1주일간 실온에서 방치한 후 150mm 여과지로 2차 여과시켜 본 발명 발효 허브 추출물을 제조하였다.The lactic acid bacteria fermented product obtained in the second step is centrifuged to remove sediment and cells, and the fermentation broth is recovered. The same amount of distilled water as an extraction solvent was added to the obtained fermentation broth and heated in an extractor equipped with a cooling condenser at a temperature of 80 ° C for 6 hours to recover the distillate, and separately, the remaining fermentation broth from the above step was extracted with an extraction solvent and fermented. get an extract The fermented extract obtained above was first filtered through a 300 mesh filter paper, left at room temperature for one week, and then filtered through a second filter paper through a 150 mm filter paper to prepare the fermented herb extract of the present invention.
상기 제 1단계의 허브는 로즈마리, 라벤더, 세이지, 바실, 민트, 캐모마일, 오레가노, 레몬밤 및 스테비아 군에서 선택되는 어느 하나 이상을 사용할 수 있으며 가장 바람직하게는 4종류 이상의 허브를 동량(w/w)으로 혼합하여 사용하는 것이다.As the herb of the first step, any one or more selected from the group of rosemary, lavender, sage, basil, mint, chamomile, oregano, lemon balm, and stevia may be used, and most preferably four or more herbs are used in equal amounts (w/w). ) to be used in combination.
상기 제 2단계의 식물성 유산균은 락토바실러스 속이면 제한없이 사용할 수 있으나 락토바실러스 플란타룸(L. plantarum, KFCC-11028), 락토바실러스 사케이(L. sakei, KFCC 11383P), 락토바실러스 랙티스(L. lactice, KCCM 11159P)중 어느 하나를 선택하는 것이 바람직하다. 상기 '식물성 유산균'이란 유산균이 분리된 원재료가 식물인 것을 특징으로 하는 유산균이다.The vegetable lactic acid bacteria of the second step can be used without limitation as long as they are of the genus Lactobacillus, but Lactobacillus plantarum (L. plantarum, KFCC-11028), Lactobacillus sakei (L. sakei, KFCC 11383P), Lactobacillus lactis (L. It is preferable to select any one of lactice, KCCM 11159P). The 'vegetable lactic acid bacteria' is a lactic acid bacteria characterized in that the raw material from which the lactic acid bacteria are isolated is a plant.
또한 상기 제 2단계의 유산균 배양배지는 MRS(Man Rogosa Sharpe), 락토오스, YM(Yeast and Mold), M17 또는 ART(Asparagine Enrichment Broth)배지를 사용할 수 있으나 MRS배지를 사용하는 것이 가장 바람직하다.In addition, the lactic acid bacteria culture medium of the second step may be MRS (Man Rogosa Sharpe), lactose, YM (Yeast and Mold), M17 or ART (Asparagine Enrichment Broth) medium, but it is most preferable to use MRS medium.
또한 상기 제 2단계의 유산균주의 접종량은 제 1단계의 허브식물 1kg 대비 1×108~5×108cell을 접종한다.In addition, the inoculation amount of the lactic acid strain in the second step is inoculated with 1×10 8 to 5×10 8 cells compared to 1 kg of the herb plant in the first step.
상기 제 3 단계의 추출용매는 증류수 및/또는 유기용매를 사용할 수 있으나 가장 바람직하기로는 증류수를 사용하는 것이다. 상기 유기용매는 탄소수 1 내지 4의 저금알코올, 프로필렌글리콜, 초산에틸, 부틸렌글리콜, 글리세린, 에틸아세티이트, 헥산, 메틸렌클로라이드중 어느 하나 이상을 사용할 수 있다. Distilled water and/or an organic solvent may be used as the extraction solvent in the third step, but distilled water is most preferably used. As the organic solvent, any one or more of low alcohol having 1 to 4 carbon atoms, propylene glycol, ethyl acetate, butylene glycol, glycerin, ethyl acetate, hexane, and methylene chloride may be used.
또한 제 3단계의 발효액과 추출용매의 혼합비는 중량기준으로 50:50 ~ 25:75인 것이 바람직하다.In addition, the mixing ratio of the fermentation broth and the extraction solvent in the third step is preferably 50:50 to 25:75 by weight.
상기 본 발명에 따라 제조된 발효 허브 추출물은 면역활성, 소화불량, 설사, 변비에 대한 예방 및 개선 기능성 식품 조성물로 이용될 수 있다.The fermented herbal extract prepared according to the present invention can be used as a functional food composition for preventing and improving immune activity, indigestion, diarrhea, and constipation.
본 발명의 발효 허브 추출물을 첨가할 수 있는 식품 조성물로는 예를 들어, 각종 음료, 껌, 차, 비타민 복합제 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실,채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)을 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다. Food compositions to which the fermented herb extract of the present invention can be added include, for example, various beverages, chewing gum, tea, and vitamin complexes. In addition, in the present invention, the food includes special nutritional food (eg, formula milk, infant food, baby food, etc.), processed meat product, fish meat product, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplement food, seasoning food ( For example, soy sauce, soybean paste, gochujang, mixed paste, etc.), sauces, confectionery (eg, snacks), dairy products (eg, fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickles, etc.), drinks ( Examples include, but are not limited to, fruit and vegetable beverages, soy milk, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.). The food, beverage or food additive may be prepared by a conventional manufacturing method.
상기 기능성 식품 조성물이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. 상기 기능성 식품 조성물에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 보조제, 응고제, 희석제 또는 생리활성 성분을 포함시킬 수 있고 분말제, 정제, 캡슐, 겔제 등을 더욱 포함할 수 있다.The functional food composition refers to a food group or food composition that has added value so that the function of the food acts for a specific purpose by using physical, biochemical, or bioengineering methods, etc. It refers to food designed and processed to fully express the body control function related to the living body. The functional food composition may include a food-acceptable food auxiliary additive, and may include appropriate carriers, adjuvants, coagulants, diluents, or physiologically active ingredients commonly used in the manufacture of functional foods, and may include powders, tablets, It may further include capsules, gels, and the like.
이하, 본 발명을 실시예와 도면에 의거 더욱 상세하게 설명한다. 그러나 하기 실시예는 본 발명을 예시하기 위한 것에 불과하며 본 발명의 권리범위를 한정하는 것으로 의도되지는 않는다.
Hereinafter, the present invention will be described in more detail based on examples and drawings. However, the following examples are only for illustrating the present invention and are not intended to limit the scope of the present invention.
본 발명 발효 허브 추출물의 허브는 청주 근교의 상수허브랜드 농장에서 채취한 로즈마리, 라벤더, 세이지, 바실, 페퍼민트, 캐모마일, 오레가노, 레몬밤, 스테비아를 각각 건조하고 분쇄하여 건조분말로 사용하였다. 또한 유산균은 락토바실러스 플란타룸(L. plantarum, KFCC-11028)을 한국미생물보존센터에서 분양받아 사용하였으며 유산균 배양배지는 MRS배지(DifcoTM MRS)를 BD에서 구매하였다.
Herbs of the fermented herb extract of the present invention were dried and pulverized from rosemary, lavender, sage, basil, peppermint, chamomile, oregano, lemon balm, and stevia collected from Sangsu Herb Brand Farm near Cheongju, respectively, and used as dry powder. In addition, lactobacillus plantarum (L. plantarum, KFCC-11028) was purchased from the Korea Microorganism Conservation Center and used as lactic acid bacteria culture medium. MRS medium (Difco TM MRS) was purchased from BD.
<실시예 1> 발효 허브 추출물 제조<Example 1> Preparation of fermented herb extract
허브로서 로즈마리분말 900 g과 동량의 증류수 900 g을 발효조에 넣고 100℃에서 5분간 살균처리한 후 37℃가 되도록 방치하였다. 그 다음 이와 별도로 MRS 배지에서 액상배양한 락토바실러스 플란타룸(L. plantarum, KFCC-11028) 200mL(1 X 108cell)을 상기 발효조에 넣고 온도 37℃, pH 7, 교반속도 100 rpm의 발효조건으로 3일간 발효시켰다. 상기단계에서 얻은 발효물을 원심분리한 후 침전물과 균체를 제거하여 발효액 1.2 L를 얻었다. 상기단계에서 얻은 발효액에 증류수 900 g을 첨가하고 이를 냉각 콘덴서가 달린 추출기에 넣고 온도 80℃로 6시간 가열한 후 증류되어 나오는 증류액을 회수하여 증류액 약 2 L를 얻었다. 상기에서 얻은 발효추출물은 300메쉬 여과지로 1차 여과하고 1주일간 실온에서 방치한 후 150mm 여과지로 2차 여과시켜 본 발명 발효 로즈마리 추출물을 제조하였다.As a herb, 900 g of rosemary powder and 900 g of the same amount of distilled water were put into a fermenter, sterilized at 100 ° C for 5 minutes, and then left at 37 ° C. Then, 200mL (1 X 10 8 cell) of Lactobacillus plantarum (L. plantarum, KFCC-11028), which was separately cultured in liquid phase in the MRS medium, was put into the fermenter and fermented at a temperature of 37°C, pH 7, and stirring speed of 100 rpm. Conditions were fermented for 3 days. After centrifuging the fermented product obtained in the above step, 1.2 L of the fermentation broth was obtained by removing the precipitate and the cells. 900 g of distilled water was added to the fermentation broth obtained in the above step, put in an extractor equipped with a cooling condenser, and heated at a temperature of 80 ° C. for 6 hours, and the distillate distilled out was recovered to obtain about 2 L of distillate. The fermented extract obtained above was first filtered through a 300 mesh filter paper, left at room temperature for one week, and then filtered through a second filter paper through a 150 mm filter paper to prepare the fermented rosemary extract of the present invention.
상기 방법과 동일한 방법으로, 발효 라벤더 추출물, 발효 세이지 추출물, 발효 바실 추출물, 발효 민트 추출물, 발효 캐모마일 추출물, 발효 오레가노 추출물, 발효 레몬밤 추출물, 발효 스테비아 추출물을 각각 제조하였다.
Fermented lavender extract, fermented sage extract, fermented basil extract, fermented mint extract, fermented chamomile extract, fermented oregano extract, fermented lemon balm extract, and fermented stevia extract were prepared in the same manner as above.
<실시예 2> 혼합 발효 허브 추출물 제조<Example 2> Preparation of mixed fermented herbal extract
상기 실시예 1과 달리 혼합 발효 허브 추출물은 하기와 같이 제조하였다. 로즈마리분말 100 g, 라벤더분말 100 g, 세이지분말 100 g, 바실분말 100 g, 페퍼민트분말 100 g, 캐모마일분말 100 g, 오레가노분말 100 g, 레몬밤분말 100 g 및 스테비아분말 100 g을 혼합한 허브 혼합분말 900 g을 사용하여 혼합 발효 허브 추출물 800 L를 제조하였다. 구체적인 제조방법은 상기 실시예 1 같다.
Unlike Example 1, the mixed fermented herb extract was prepared as follows. 100 g of rosemary powder, 100 g of lavender powder, 100 g of sage powder, 100 g of basil powder, 100 g of peppermint powder, 100 g of chamomile powder, 100 g of oregano powder, 100 g of lemon balm powder, and 100 g of stevia powder. 800 L of mixed fermented herbal extract was prepared using 900 g of powder. The specific manufacturing method is the same as in Example 1 above.
<비교예1> 혼합 허브 추출물의 제조<Comparative Example 1> Preparation of mixed herbal extract
로즈마리분말 100 g, 라벤더분말 100 g, 세이지분말 100 g, 바실분말 100 g, 페퍼민트분말 100 g, 캐모마일분말 100 g, 오레가노분말 100 g, 레몬밤분말 100 g 및 스테비아분말 100 g을 혼합한 허브 혼합분말 900 g과 동량의 증류수 900 g을 냉각 콘덴서가 달린 추출기에 넣고 온도 80℃로 6시간 가열한 후 증류되어 나오는 증류액을 회수하여 허브 추출물을 얻었다.
100 g of rosemary powder, 100 g of lavender powder, 100 g of sage powder, 100 g of basil powder, 100 g of peppermint powder, 100 g of chamomile powder, 100 g of oregano powder, 100 g of lemon balm powder, and 100 g of stevia powder. 900 g of the powder and 900 g of the same amount of distilled water were put in an extractor equipped with a cooling condenser and heated at a temperature of 80 ° C. for 6 hours, and the distillate distilled out was recovered to obtain an herbal extract.
<< 제조예manufacturing example 1> 혼합 발효 허브 추출물을 함유하는 식품 조성물 제조 1> Preparation of a food composition containing mixed fermented herbal extracts
(1) 가루 및 과립형 제조(1) powder and granular manufacturing
상기 실시예 2에서 제조한 혼합 발효 허브 추출물 및 비교예 1의 혼합 허브 추출물을 하기 [표 1]의 함량 비율로 가루형태와 과립형태로 각각 제조하였다.
The mixed fermented herbal extract prepared in Example 2 and the mixed herbal extract of Comparative Example 1 were prepared in powder form and granular form at the content ratios shown in [Table 1], respectively.
Raw material
[주] 혼합 허브 분말 : 로즈마리, 라벤더, 민트, 캐모마일, 세이지, 바실, 타임, 펜넬, 레몬밤을 1:1:1:1:1:1:1:1:1(중량%)로 혼합하여 분쇄한 분말[Note] Mixed herb powder: Mix rosemary, lavender, mint, chamomile, sage, basil, thyme, fennel, and lemon balm in a ratio of 1:1:1:1:1:1:1:1:1 (% by weight) crushed powder
(2) 음료 제조(2) Beverage manufacturing
상기 실시예 2에서 제조한 혼합 발효 허브 추출물 및 비교예 1에서 제조한 혼합 허브 추출물을 하기 [표 2]의 배합비로 꿀, 식초, 올리고당, 비타민C, 구연산, 물과 혼합하여 음료를 각각 제조하였다.
The mixed fermented herb extract prepared in Example 2 and the mixed herb extract prepared in Comparative Example 1 were mixed with honey, vinegar, oligosaccharide, vitamin C, citric acid, and water in the mixing ratio shown in [Table 2] to prepare beverages, respectively. .
<< 실험예Experimental example 1> 본 발명 혼합 발효 허브 추출물의 면역증강 효과 평가 1> Evaluation of the immune enhancing effect of the mixed fermented herbal extract of the present invention
(1) 실험동물의 사육조건 및 장기무게와 체중 측정(1) Breeding conditions and organ weight and body weight measurement of experimental animals
생후 6주령의 암컷 Balb/c 마우스를 분양 받아 난괴법으로 군을 나누어 케이지에 한 마리씩 사육하고 5주 간 사육하였다. 사육실의 실내 온도는 22±2℃, 습도는 50±5%, 전등은 낮 12시간, 밤 12시간으로 조절하였다. 식이는 일반 식이와 혼합 허브 추출물 첨가 식이 및 혼합 발효 허브 추출물 함유 식이 총 3군으로 나누어 각 군 당 8마리씩 배정하였으며 식이는 하루에 한번씩 5주 간 급여하였다. 장기 무게는 5주 간 급여가 끝난 후 측정하였고 체중은 일주일에 한번씩 일정한 시간에 측정하였다. 실험동물의 장기는 적출하여 생리식염수에 세척한 후 흡수지로 물기를 제거하고 무게를 측정하였다.Six-week-old female Balb/c mice were distributed and divided into groups using the egg mass method, and they were raised one by one in a cage and reared for 5 weeks. The indoor temperature of the breeding room was 22 ± 2 ℃, humidity was 50 ± 5%, and the lights were adjusted to 12 hours during the day and 12 hours at night. The diet was divided into 3 groups: general diet, mixed herb extract supplemented diet, and mixed fermented herb extract containing diet, and 8 animals were assigned to each group, and the diet was fed once a day for 5 weeks. Organ weights were measured after 5 weeks of feeding, and body weights were measured once a week at regular times. The organs of the experimental animals were removed, washed in physiological saline, dried with absorbent paper, and weighed.
실험결과, [표 3]에서 보는 바와 같이 일반 식이 대조군이 혼합 허브 추출물 함유 식이군 및 혼합 발효 허브 추출물 함유 식이군에 비해 유의적으로 높게 나타났다.
As a result of the experiment, as shown in [Table 3], the normal diet control group was significantly higher than the mixed herb extract-containing diet group and the mixed fermented herb extract-containing diet group.
[주] Values are mean ±SE for 8 animals in each group.[Note] Values are mean ±SE for 8 animals in each group.
1)One)
FERFER
, food efficiency ration = weight gain(g/day)/food in take(g/day) × 100, food efficiency ration = weight gain (g/day)/food in take (g/day) × 100
또, [표 4]에서 보는 바와 같이 심장, 간, 신장, 비장 조직의 무게는 유의적인 차이를 보이지 않았다.
In addition, as shown in [Table 4], there was no significant difference in the weight of heart, liver, kidney, and spleen tissues.
[주] Values are mean ±SE for 8 animals in each group.[Note] Values are mean ±SE for 8 animals in each group.
(2) 비장세포 증식능 측정(2) Measurement of splenocyte proliferative capacity
상기 5주 간 사육을 한 마우스에 이산화탄소로 희생시킨 마우스로부터 무균적으로 비장을 적출하여 RPMI 1640으로 씻은 후 멸균 유리봉으로 상기 비장을 분쇄하여 세포를 유리시켰다. 분리된 세포 현탁액을 150 mesh stainless steel sieve에 통과시켜 상기 배지로 2번 세척하고 원심분리하였다(3000 rpm, 4℃, 10분). 원심분리한 비장의 적혈구를 제거하기 위해 Tris-buffered ammonium chloride(0.87% NH4Cl, pH 7.2)에 5분간 현탁시켰다. 상기 적혈구가 제거 된 비장세포 현탁액에 분산시켜 세포수를 측정하였다. 세포는 5×106 cell/mL로 분산시킨 후 96 well plate에 분주하여 비장세포 증식능을 측정하였고, cytokine 분비량을 측정하기 위해 2×106 cell/mL가 되도록 조정한 후 24 well에 분주하고 각 군 당 양의 대조군으로 LPS (15 g/mL)를 100 L씩 분주하고 대조군에는 10% FBS-RPMI를 동량 분주한 후 각 plate는 37℃, 5% CO2 배양기에서 48시간 동안 배양한 후 배양액을 이용하여 실험하였다. The spleen was aseptically removed from the mouse that had been raised for 5 weeks and sacrificed with carbon dioxide, washed with RPMI 1640, and the spleen was pulverized with a sterile glass rod to release cells. The separated cell suspension was passed through a 150 mesh stainless steel sieve, washed twice with the medium, and centrifuged (3000 rpm, 4° C., 10 minutes). To remove red blood cells from the centrifuged spleen, they were suspended in Tris-buffered ammonium chloride (0.87% NH 4 Cl, pH 7.2) for 5 minutes. The number of cells was measured by dispersing in the splenocyte suspension from which the red blood cells were removed. The cells were dispersed at 5×10 6 cell/mL and then dispensed into a 96 well plate to measure the proliferative capacity of splenocytes. In order to measure the amount of cytokine secretion, after adjusting to 2×10 6 cell/mL, the cells were dispensed into 24 wells and each As a positive control for each group, 100 L of LPS (15 g/mL) was dispensed and the same amount of 10% FBS-RPMI was dispensed into the control group, and each plate was incubated for 48 hours in a 37°C, 5% CO 2 incubator, followed by culture medium. was experimented with.
MTT assay를 이용하여 비장세포 증식능을 측정하였다. T세포를 선택적으로 증가시키는 ConA와 B세포를 선택적으로 증가시키는 LPS(lipopolysaccharide)를 mitogen으로 첨가하였고, mitogen을 첨가하지 않은 정상대조군의 비장 증식능을 1로 계산한 proliferation index를 나타내었다.Splenocyte proliferative capacity was measured using MTT assay. ConA, which selectively increases T cells, and lipopolysaccharide (LPS), which selectively increases B cells, were added as mitogens.
실험결과, [표 5]에서 나타낸 바와 같이 mitogen을 첨가하지 않을 시 모든 그룹에서 유의적인 차이가 없었고, ConA와 LPS 첨가한 경우, 혼합 발효 허브 추출물 함유 식이군에서 일반식이 대조군에 비해 증식능이 유의적으로 높게 나타난 반면, 혼합 허브 추출물 함유 식이군에서는 일반식이 대조군과 유의적인 차이를 보이지 않았다.
As a result of the experiment, as shown in [Table 5], there was no significant difference in all groups when mitogen was not added, and when ConA and LPS were added, in the group containing mixed fermented herb extracts, the proliferative ability was significant compared to the control group However, in the mixed herbal extract-containing diet group, there was no significant difference between the general diet and the control group.
[주] Values are mean ±SE for 8 animals in each group.[Note] Values are mean ±SE for 8 animals in each group.
<< 실험예Experimental example 2> 본 발명 혼합 발효 허브 추출물 식품의 소화불량 개선 효과 평가 2> Evaluation of dyspepsia improvement effect of the mixed fermented herb extract food of the present invention
소화불량으로 생활에 불편함을 겪는 20 ~ 40대 20명을 대상으로 소화불량 개선 효과 검사를 실시하였다. 실험단은 상기 제조예에 혼합 발효 허브 추출물을 함유하는 식품 조성물을 일주일간 1일 2회 복용하고 하기 문항에 답하였다.The indigestion improvement effect test was conducted on 20 people in their 20s and 40s who suffer from indigestion and inconvenience in life. The experimental group took the food composition containing the mixed fermented herb extract in Preparation Example twice a day for a week and answered the following questions.
실험결과, [표 6]에 나타낸 바와 같이 본 발명의 혼합 허브 추출물을 함유하는 식품 조성물을 섭취한 사람들은 50% 이상의 사람이 소화불량이 개선되었으며 혼합 발효 허브 추출물을 함유하는 식품 조성물을 섭취한 사람들 가운데 80% 이상의 사람이 소화불량이 개선된 것으로 나타났다.
As a result of the experiment, as shown in [Table 6], more than 50% of people who consumed the food composition containing the mixed herbal extracts of the present invention had improved indigestion, and those who consumed the food composition containing the mixed fermented herbal extracts More than 80% of people showed improvement in indigestion.
<< 실험예Experimental example 3> 본 발명 혼합 발효 허브 추출물의 설사 개선 효과 평가 3> Evaluation of diarrhea improvement effect of the mixed fermented herbal extract of the present invention
설사로 생활에 불편함을 겪는 20 ~ 40대 20명을 대상으로 설사 개선 효과 검사를 실시하였다. 실험단은 상기 제조예에 혼합 발효 허브 추출물을 함유하는 식품 조성물을 일주일간 1일 2회 복용하고 하기 문항에 답하였다.The diarrhea improvement effect test was conducted on 20 people in their 20s to 40s who suffered from diarrhea in their lives. The experimental group took the food composition containing the mixed fermented herb extract in Preparation Example twice a day for a week and answered the following questions.
실험결과, [표 7]에 나타낸 바와 같이 본 발명의 혼합 허브 추출물을 함유하는 식품 조성물을 섭취한 사람들은 60% 이상의 사람이 설사가 개선되었으며 혼합 발효 허브 추출물을 함유하는 식품 조성물을 섭취한 사람들 가운데 90% 이상의 사람이 설사가 개선된 것으로 나타났다.
As a result of the experiment, as shown in [Table 7], diarrhea was improved in more than 60% of people who consumed the food composition containing the mixed herbal extract of the present invention, and among those who consumed the food composition containing the mixed fermented herbal extract Diarrhea improved in over 90% of people.
<< 실험예Experimental example 4> 본 발명 혼합 발효 허브 추출물의 변비 개선 효과 평가 4> Evaluation of the Constipation Improvement Effect of the Mixed Fermented Herb Extract of the Present Invention
변비로 생활에 불편함을 겪는 20 ~ 40대 20명을 대상으로 변비 개선 효과 검사를 실시하였다. 실험단은 상기 제조예에 혼합 발효 허브 추출물을 함유하는 식품 조성물을 일주일간 1일 2회 복용하고 하기 문항에 답하였다.Constipation improvement effect test was conducted targeting 20 people in their 20s to 40s suffering from constipation. The experimental group took the food composition containing the mixed fermented herb extract in Preparation Example twice a day for a week and answered the following questions.
실험결과, [표 8]에 나타낸 바와 같이 본 발명의 혼합 허브 추출물을 함유하는 식품 조성물을 섭취한 사람들은 45% 이상의 사람이 변비가 개선되었으며 혼합 발효 허브 추출물을 함유하는 식품 조성물을 섭취한 사람들 가운데 70% 이상의 사람이 변비가 개선된 것으로 나타났다.
As a result of the experiment, as shown in [Table 8], constipation was improved in 45% or more of those who consumed the food composition containing the mixed herbal extract of the present invention, and among those who consumed the food composition containing the mixed fermented herbal extract More than 70% of people reported an improvement in constipation.
본 발명은 식물성 유산균 발효 혼합 허브 식물 추출물을 유효성분으로 함유하는 면역활성, 소화불량, 설사 및 변비 예방 또는 개선 기능성 식품 조성물을 제공하는 효과가 있으며 특히 분말, 과립, 액상, 음료 등 제형으로 식품용 신소재로서 사용될 수 있는 뛰어난 효과가 있다. 또 발효 허브 추출물에 함유되어 있는 유용한 성분이 함유된 식품 조성물을 제공함으로써 면역활성, 소화불량, 설사, 변비 예방 및 개선 기능을 향상시킬 수 있는 뛰어난 효과가 있으므로 식품 산업적으로 매우 유용한 발명인 것이다.The present invention has the effect of providing a functional food composition for preventing or improving immune activity, indigestion, diarrhea and constipation containing vegetable lactic acid bacteria fermented mixed herbal plant extracts as active ingredients, and in particular, in powder, granule, liquid, beverage, etc. formulations for food use There is an excellent effect that can be used as a new material. In addition, it is a very useful invention in the food industry because it has an excellent effect of improving immune activity, indigestion, diarrhea, and constipation prevention and improvement by providing a food composition containing useful ingredients contained in fermented herb extracts.
Claims (5)
Mixed herbs of rosemary, lavender, sage, basil, mint, chamomile, oregano, lemon balm, and stevia in an equal weight ratio (w/w) are dried and powdered, and then the same amount of distilled water is added and heated at 100℃ for 5 minutes. Preparing a fermentation raw material cooled to 37 ° C. by high-temperature sterilization; Lactobacillus plantarum (L. plantarum, KFCC-11028), Lactobacillus sakei (KFCC 11383P), Lactobacillus lectis (L. lactice, KCCM 11159P) selected from the fermentation raw material obtained in the above step Obtaining a vegetable lactic acid bacteria fermented product by inoculating any one vegetable lactic acid bacteria and fermenting for 3 to 5 days under conditions of pH 7 and 100 to 120 rpm at 35 to 37 ° C; Adding an equal amount of distilled water to the fermentation broth obtained by centrifuging the lactic acid bacteria fermentation product obtained in the lactic acid bacteria fermentation step, and recovering a distillation extract by heating and distilling in an extractor; Separately, extracting the fermentation broth remaining in the distillation extraction recovery step with an extraction solvent to obtain a fermentation extract; Method for producing a vegetable lactic acid bacteria fermented mixed herb extract, characterized in that it comprises all the steps of filtering the fermented extract obtained in the solvent extraction step with filter paper.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150126000A KR102516968B1 (en) | 2015-09-07 | 2015-09-07 | Food composition comprising fermented herbs extract for preventing or improving of immunity, dyspepsia, diarrhea and constipation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150126000A KR102516968B1 (en) | 2015-09-07 | 2015-09-07 | Food composition comprising fermented herbs extract for preventing or improving of immunity, dyspepsia, diarrhea and constipation |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170029103A KR20170029103A (en) | 2017-03-15 |
KR102516968B1 true KR102516968B1 (en) | 2023-03-31 |
Family
ID=58403267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150126000A KR102516968B1 (en) | 2015-09-07 | 2015-09-07 | Food composition comprising fermented herbs extract for preventing or improving of immunity, dyspepsia, diarrhea and constipation |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102516968B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102355366B1 (en) * | 2019-11-14 | 2022-01-25 | 재단법인 전남바이오산업진흥원 | Steak sauce and its preparation method |
KR102485367B1 (en) * | 2021-12-27 | 2023-01-10 | (주)제이에스씨컴퍼니 | Sauce composition for octopus or squid and manufacturing method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090012762A (en) * | 2007-07-31 | 2009-02-04 | 정찬수 | Herb fermentation tea and a process of herb fermentation tea |
KR20110118911A (en) * | 2010-04-26 | 2011-11-02 | (주)웰조이 | Lactic acid bacteria fermented extract using cereals and herb medicine materials, and method of preparing thereof |
KR101472190B1 (en) * | 2012-12-24 | 2014-12-12 | 주식회사 풀무원 | Composition for preventing, treating or improving constipation comprising plant originated tyndalized lactic acid bacteria, Lactobacillus plantarum PMO08 dead cell as an active ingredient |
-
2015
- 2015-09-07 KR KR1020150126000A patent/KR102516968B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20170029103A (en) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102813064B (en) | Plant extract feed additive for piglets | |
CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
KR101252639B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Ssanghwatang and Fermentation Product Thereof with Lactic Acid Bacteria | |
David | Preparation of herbal Shrikhand prepared with basil (Ocimum basilicum) extract | |
KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
CN105685620A (en) | Moringa oleifera oral liquid and preparation method thereof | |
KR102516968B1 (en) | Food composition comprising fermented herbs extract for preventing or improving of immunity, dyspepsia, diarrhea and constipation | |
JP5943406B2 (en) | Composition for maintaining the survival of bifidobacteria or lactic acid bacteria | |
KR102305931B1 (en) | A food composition for improving circulation of blood and increasing functions of immune comprising natural extracts | |
KR102139732B1 (en) | Composition for improving immune activity containing lactobacillus | |
KR20200066888A (en) | Manufacturing method for functional feed composition | |
KR20160049732A (en) | Method for preparing fermented bitter melon extract and a fu nctional food sauce and a functional fermented drink manufactured thereby | |
Mahmoudi et al. | An introductory review on increasing the survival of probiotic bacteria in dairy products using essential oil | |
KR102168192B1 (en) | Healthful mixed tea development using fermented herbs, fruits and shiitake | |
US20220016193A1 (en) | ANTIBACTERIAL AND ANTIVIRUS COMPOSITION COMPRISING Extract of CANNABIS SATIVA L. | |
KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
Jia et al. | Hawk Tea, a traditional and healthy natural beverage in South China | |
CN104758555B (en) | Treat the Chinese herbal medicine of seawater fish bacterial disease | |
KR101642806B1 (en) | A composition for preventing or treating cognitive impairment comprising an extracts of steamed and fermented codonopsis lanceolata | |
KR101600884B1 (en) | Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient | |
JP6541047B1 (en) | Oral composition | |
KR101949557B1 (en) | Composition for immune enhancing activity containingextract of aralia cordata | |
Onoruoiza et al. | A Review on the Effects of Functional Food on Humans and Microorganisms | |
Mahmoudi | An overview of using some essential oils in functional dairy products from Iran |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |